In June, a clinical trial showed that a twice-yearly injection was as effective as daily oral medication in preventing HIV. The trial was so successful that researchers were instructed to halt the study and offer the injection to all participants immediately. This development is part of a larger push towards longer-acting HIV medications, which reduce the pill burden and stigma associated with daily medication. However, for these innovations to reach their full potential, Medicaid, a major source of HIV care financing in the US, must take action to ensure access to these treatments, especially for vulnerable communities disproportionately affected by HIV.
Source link
Medicaid should prepare now to cover twice-yearly PrEP
